Timothy F. Feltes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Timothy F. Feltes has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Henry M Sondheimer
2 shared publicationsAllison K Cabalka
1 shared publication- Christoph Aebi
Division of Paediatric Infectious Diseases, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
1 shared publication David A Carlin
1 shared publicationE Simoes
Department of Pediatric Cardiology, Columbus Children’s Hospital and Ohio State University, USA
1 shared publicationEdward M Connor
1 shared publication
Latest Publications
- 29 August 2007
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 7 (9) , 1471-1480
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease
Respiratory syncytial virus (RSV) is a significant pathogen for infants and children with congenital heart disease. Non-sustained immunity and failure to develop an effective vaccine has steered RSV management toward a passive immunotherapy strategy in at-risk children. Palivizumab is a humanized murine monoclonal antibody targeting the RSV envelope F glycoprotein. In a Phase III clinical trial palivizumab significantly reduced RSV hospitalization in children with significant congenital heart disease and was proven to be safe. Palivizumab is one of the first monoclonal antibodies to significantly impact a pediatric disease.
- 29 August 2007
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 7 (9) , 1471-1480
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease
Respiratory syncytial virus (RSV) is a significant pathogen for infants and children with congenital heart disease. Non-sustained immunity and failure to develop an effective vaccine has steered RSV management toward a passive immunotherapy strategy in at-risk children. Palivizumab is a humanized murine monoclonal antibody targeting the RSV envelope F glycoprotein. In a Phase III clinical trial palivizumab significantly reduced RSV hospitalization in children with significant congenital heart disease and was proven to be safe. Palivizumab is one of the first monoclonal antibodies to significantly impact a pediatric disease.
- 1 September 2006
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 16 (S3) , 136-143
The current state of infection with respiratory syncytial virus in the setting of congenital cardiac malformations
A long with prematurity and chronic lung disease, the presence of congenital cardiac disease in infants and young children is a significant risk for the clinical consequences of an illness produced by infection with the respiratory syncytial virus. 1 In this review, we present a current understanding of such illnesses, their prevention, and their treatment.
- 1 September 2006
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 16 (S3) , 136-143
The current state of infection with respiratory syncytial virus in the setting of congenital cardiac malformations
A long with prematurity and chronic lung disease, the presence of congenital cardiac disease in infants and young children is a significant risk for the clinical consequences of an illness produced by infection with the respiratory syncytial virus. 1 In this review, we present a current understanding of such illnesses, their prevention, and their treatment.
- Open Access
- 1 August 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 90 (8) , 875-877
Palivizumab prophylaxis in haemodynamically significant congenital heart disease * Authors' reply
They suggest that the rate of hospitalisation in their population of patients from the Canton of Bern, Switzerland was as much as four times lower than rates previously reported in the United States. Based on these results they concluded that the unrestricted use of palivizumab to prevent RSV hospitalisation was not justified.
- 1 August 2005
- Published by BMJ in Archives of Disease in Childhood
- Vol. 90 (8) , 875-877
Open AccessPalivizumab prophylaxis in haemodynamically significant congenital heart disease * Authors' reply
They suggest that the rate of hospitalisation in their population of patients from the Canton of Bern, Switzerland was as much as four times lower than rates previously reported in the United States. Based on these results they concluded that the unrestricted use of palivizumab to prevent RSV hospitalisation was not justified.
- 3 May 2005
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 15 (3) , 266-273
Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations
All newborn infants have limited pulmonary reserve compared with older children. This puts them at increased risk of respiratory complications, such as those associated with infection by the respiratory syncytial virus. Young children with congenital cardiac disease are particularly likely to suffer severe disease related to infection by the virus. In these children, the extreme vulnerability of the lung to pulmonary oedema is compounded by the additional burden caused by the respiratory syncytial virus.In addition to the well-documented acute pulmonary effects of infection with the respiratory syncytial virus, there may also be consequent long-term respiratory morbidity. Clinical studies have shown that infection by the virus in infancy is associated with a higher risk of developing subsequent bronchial obstructive disease. Much debate surrounds the mechanisms underlying this association. It is thought that a combined immunological and neurogenic response mechanism is likely. Prevention of severe respiratory disease in infants and young children with congenital heart disease due to infection by the virus may, therefore, offer both immediate and long-term benefits. Indeed, an increasing body of evidence supports this hypothesis, indicating a clinical rationale for prophylaxis against the virus in infancy, in order to reduce the chance of developing reactive airways disease and asthma in later life.
- 3 May 2005
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 15 (3) , 266-273
Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations
All newborn infants have limited pulmonary reserve compared with older children. This puts them at increased risk of respiratory complications, such as those associated with infection by the respiratory syncytial virus. Young children with congenital cardiac disease are particularly likely to suffer severe disease related to infection by the virus. In these children, the extreme vulnerability of the lung to pulmonary oedema is compounded by the additional burden caused by the respiratory syncytial virus.In addition to the well-documented acute pulmonary effects of infection with the respiratory syncytial virus, there may also be consequent long-term respiratory morbidity. Clinical studies have shown that infection by the virus in infancy is associated with a higher risk of developing subsequent bronchial obstructive disease. Much debate surrounds the mechanisms underlying this association. It is thought that a combined immunological and neurogenic response mechanism is likely. Prevention of severe respiratory disease in infants and young children with congenital heart disease due to infection by the virus may, therefore, offer both immediate and long-term benefits. Indeed, an increasing body of evidence supports this hypothesis, indicating a clinical rationale for prophylaxis against the virus in infancy, in order to reduce the chance of developing reactive airways disease and asthma in later life.
- Top Cited Papers
- 1 October 2003
- Published by Elsevier in The Journal of Pediatrics
- Vol. 143 (4) , 532-540
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
- 1 October 2003
- Published by Elsevier in The Journal of Pediatrics
- Vol. 143 (4) , 532-540
Top Cited PapersPalivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease